Gobbi C, et al. Real-world data from the TACO (teriflunomide in relapsing remitting multiple sclerosis patients assessing clinical benefit and patient-reported outcomes) study. Poster 1371. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Masitinib én riluzol vertraagt ALS-progressie
okt 2017 | Neuro-musculair